rs16969968
Positions:
Variant summary
Our verdict is Benign. Variant got -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_000745.4(CHRNA5):c.1192G>A(p.Asp398Asn) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.302 in 1,613,800 control chromosomes in the GnomAD database, including 79,728 homozygotes. In-silico tool predicts a benign outcome for this variant. 12/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as drug response (★★★).
Frequency
Genomes: 𝑓 0.24 ( 5789 hom., cov: 32)
Exomes 𝑓: 0.31 ( 73939 hom. )
Consequence
CHRNA5
NM_000745.4 missense
NM_000745.4 missense
Scores
1
2
15
Clinical Significance
Conservation
PhyloP100: 7.89
Genes affected
CHRNA5 (HGNC:1959): (cholinergic receptor nicotinic alpha 5 subunit) The protein encoded by this gene is a nicotinic acetylcholine receptor subunit and a member of a superfamily of ligand-gated ion channels that mediate fast signal transmission at synapses. These receptors are thought to be heteropentamers composed of separate but similar subunits. Defects in this gene have been linked to susceptibility to lung cancer type 2 (LNCR2).[provided by RefSeq, Jun 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -12 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.0011689961).
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.343 is higher than 0.05.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CHRNA5 | NM_000745.4 | c.1192G>A | p.Asp398Asn | missense_variant | 5/6 | ENST00000299565.9 | NP_000736.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CHRNA5 | ENST00000299565.9 | c.1192G>A | p.Asp398Asn | missense_variant | 5/6 | 1 | NM_000745.4 | ENSP00000299565 | P1 | |
ENST00000567141.1 | n.694C>T | non_coding_transcript_exon_variant | 1/1 |
Frequencies
GnomAD3 genomes AF: 0.240 AC: 36562AN: 152040Hom.: 5789 Cov.: 32
GnomAD3 genomes
AF:
AC:
36562
AN:
152040
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.264 AC: 66316AN: 250966Hom.: 10589 AF XY: 0.276 AC XY: 37394AN XY: 135724
GnomAD3 exomes
AF:
AC:
66316
AN:
250966
Hom.:
AF XY:
AC XY:
37394
AN XY:
135724
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.308 AC: 450162AN: 1461642Hom.: 73939 Cov.: 38 AF XY: 0.308 AC XY: 223838AN XY: 727150
GnomAD4 exome
AF:
AC:
450162
AN:
1461642
Hom.:
Cov.:
38
AF XY:
AC XY:
223838
AN XY:
727150
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.240 AC: 36562AN: 152158Hom.: 5789 Cov.: 32 AF XY: 0.238 AC XY: 17675AN XY: 74388
GnomAD4 genome
AF:
AC:
36562
AN:
152158
Hom.:
Cov.:
32
AF XY:
AC XY:
17675
AN XY:
74388
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
1210
ALSPAC
AF:
AC:
1246
ESP6500AA
AF:
AC:
274
ESP6500EA
AF:
AC:
2993
ExAC
AF:
AC:
32420
Asia WGS
AF:
AC:
401
AN:
3478
ClinVar
Significance: drug response
Submissions summary: Uncertain:1Other:3
Revision: reviewed by expert panel
LINK: link
Submissions by phenotype
Susceptibility to severe coronavirus disease (COVID-19) due to high levels of fibrinogen and C-reactive protein Uncertain:1
Uncertain significance, no assertion criteria provided | research | HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas | - | - - |
Lung cancer susceptibility 2 Other:1
risk factor, no assertion criteria provided | literature only | OMIM | Jul 27, 2010 | - - |
nicotine response - Toxicity Other:1
drug response, reviewed by expert panel | curation | PharmGKB | Mar 24, 2021 | PharmGKB Level of Evidence 2B: Variants in Level 2B clinical annotations are not in PharmGKB’s Tier 1 VIPs. These clinical annotations describe variant-drug combinations with a moderate level of evidence supporting the association. For example, the association may be found in multiple cohorts, but there may be a minority of studies that do not support the majority assertion. Level 2B clinical annotations must be supported by at least two independent publications. Drug-variant association: Toxicity |
Smoking as a quantitative trait locus 3 Other:1
risk factor, no assertion criteria provided | literature only | OMIM | Jul 27, 2010 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Uncertain
DEOGEN2
Benign
T
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Pathogenic
D
LIST_S2
Benign
T
MetaRNN
Benign
T
MetaSVM
Benign
T
MutationAssessor
Uncertain
M
MutationTaster
Benign
P;P
PrimateAI
Benign
T
PROVEAN
Benign
N
REVEL
Benign
Sift
Benign
T
Sift4G
Benign
T
Polyphen
B
Vest4
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at